1 December 2023
Update on CRYSTALIZE evidence trials Discontinuation of STABILIZE-CKD and DIALIZE-Outcomes Phase III trials AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials…
1 December 2023 JAMES HALSTEAD PLC (the ‘Group’) Chairman’s Statement to the Annual General Meeting James Halstead plc, the commercial flooring company, is holding…
30 November 2023
JPMORGAN EUROPEAN GROWTH & INCOME PLC UNAUDITED HALF YEAR RESULTS FOR THE SIX MONTHS ENDED30TH SEPTEMBER 2023 Legal Entity Identifier: 549300D8SPJFHBDGXS57 Information disclosed in accordance…
30 November 2023 TClarke plc TRADING UPDATE High Quality Order Book Now Exceeds £1.1bn TClarke plc (“the Group”), the Building Services Group, today provides…
James Latham plc (“James Latham” or the “Company”) HALF YEARLY RESULTS FOR THE PERIOD ENDED 30 SEPTEMBER 2023 Chairman’s statement Unaudited results for the…
WYNNSTAY GROUP PLC (“Wynnstay” or “the Group”) TRADING UPDATE The Board of Wynnstay, the agricultural supplies and specialist merchanting group, provides an update on…
MITCHELLS & BUTLERS PLC LEI no: 213800JHYNDNB1NS2W10 30 November 2023 FULL YEAR RESULTS (For the 53 weeks ended 30 September 2023) Highlights – Like-for-like salesa growth…
LXi REIT plc (“LXI“, the “Company” or the “Group“) INTERIM RESULTS FOR THE HALF-YEAR ENDED 30 SEPTEMBER 2023 Continuing to deliver a robust operational…